Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Chattem Boosts Acquired Brands With Ad Spend, Retail Expansion

This article was originally published in The Tan Sheet

Executive Summary

Chattem's aggressive marketing behind recently acquired brands is paying off, President and COO Robert Bosworth stated during the Lehman Brothers Back-to-School Consumer Conference Sept. 5

You may also be interested in...



Chattem To Unveil New Products In August, Reports 42 Percent Sales Growth

Chattem reported substantially higher sales growth in its latest quarter from brands it acquired in 2006 than from products it developed, but looks to boost those products' contribution to its growth with the launch of nine line extensions in early 2008

Chattem Hopes Brands Acquired From J&J Offset Cool Sales Of Pro-Therapy

For 2007, Chattem expects sales of products recently acquired from Johnson & Johnson to rival its existing "big three," of Gold Bond skin care, Icy Hot topical analgesics and Selsun medicated shampoos

MoCRA’s Adulteration Ambiguity And FDA’s New Cosmetic Recall Authority: Attorney Weighs In

The US FDA should use guidance or rulemaking to clarify MoCRA provisions related to adulteration, Amin Wasserman Gurnani attorney Angela Diesch suggested at the Independent Beauty Association’s Cosmetics Convergence Spring Symposium. Attendees also sought her take on whether the agency’s new recall authority is likely to spell an increase in cosmetic product recalls.

Latest Headlines
See All
UsernamePublicRestriction

Register

PS100880

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel